Bluelinea SA
Bluelinea Société Anonyme provides health services for elderly and disabled people in France. It offers seniors and home services, including day and night family, and elder support related services. The company also provides connected establishments services that protects residents while assisting caregivers and staff in shared accommodation between seniors, serviced residences, EHPADs, specializ… Read more
Bluelinea SA (ALBLU) - Net Assets
Latest net assets as of June 2025: €706.70K EUR
Based on the latest financial reports, Bluelinea SA (ALBLU) has net assets worth €706.70K EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€9.50 Million) and total liabilities (€8.79 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €706.70K |
| % of Total Assets | 7.44% |
| Annual Growth Rate | N/A |
| 5-Year Change | 59.33% |
| 10-Year Change | 18861.08% |
| Growth Volatility | 21174.3 |
Bluelinea SA - Net Assets Trend (2009–2024)
This chart illustrates how Bluelinea SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bluelinea SA (2009–2024)
The table below shows the annual net assets of Bluelinea SA from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €1.41 Million | -47.35% |
| 2023-12-31 | €2.68 Million | -37.61% |
| 2022-12-31 | €4.30 Million | +331.96% |
| 2021-12-31 | €-1.85 Million | -309.12% |
| 2020-12-31 | €886.46K | -60.87% |
| 2019-12-31 | €2.27 Million | -55.17% |
| 2018-12-31 | €5.05 Million | +79499.57% |
| 2017-12-31 | €6.35K | -32.02% |
| 2016-12-31 | €9.34K | +25.39% |
| 2015-12-31 | €7.45K | -99.74% |
| 2014-12-31 | €2.92 Million | +49.30% |
| 2013-12-31 | €1.96 Million | -11.76% |
| 2012-12-31 | €2.22 Million | +47.27% |
| 2011-12-31 | €1.50 Million | +1080.98% |
| 2010-12-31 | €127.40K | +134.64% |
| 2009-12-31 | €-367.77K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bluelinea SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2527462000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €2.46 Million | 173.89% |
| Other Components | €24.81 Million | 1756.81% |
| Total Equity | €1.41 Million | 100.00% |
Bluelinea SA Competitors by Market Cap
The table below lists competitors of Bluelinea SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Precision Biosensor Inc.
KQ:335810
|
$6.02 Million |
|
Ascendant Resources Inc
OTCQB:ASDRF
|
$6.02 Million |
|
Bartronics India Limited
NSE:ASMS
|
$6.02 Million |
|
Dynasty Gold Corp
PINK:DGDCF
|
$6.02 Million |
|
Electric Power Technology Limited
TWO:4529
|
$6.01 Million |
|
ALFOT Technologies Co., Ltd.
TWO:4553
|
$6.01 Million |
|
KD Chem Co. Ltd
KQ:221980
|
$6.01 Million |
|
AUSTRALIAN DAIRY NUT.GRP.
F:F9H
|
$6.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bluelinea SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,682,669 to 1,412,426, a change of -1,270,243 (-47.3%).
- Net loss of 1,270,000 reduced equity.
- Other comprehensive income increased equity by 76,994.
- Other factors decreased equity by 77,237.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-1.27 Million | -89.92% |
| Other Comprehensive Income | €76.99K | +5.45% |
| Other Changes | €-77.24K | -5.47% |
| Total Change | €- | -47.35% |
Book Value vs Market Value Analysis
This analysis compares Bluelinea SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.28x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | €-0.19 | €0.49 | x |
| 2010-12-31 | €0.07 | €0.49 | x |
| 2011-12-31 | €0.53 | €0.49 | x |
| 2012-12-31 | €1.11 | €0.49 | x |
| 2013-12-31 | €0.69 | €0.49 | x |
| 2014-12-31 | €1.01 | €0.49 | x |
| 2015-12-31 | €2.69 | €0.49 | x |
| 2016-12-31 | €2.69 | €0.49 | x |
| 2017-12-31 | €1.83 | €0.49 | x |
| 2018-12-31 | €0.93 | €0.49 | x |
| 2019-12-31 | €0.42 | €0.49 | x |
| 2020-12-31 | €0.15 | €0.49 | x |
| 2021-12-31 | €-0.30 | €0.49 | x |
| 2022-12-31 | €0.35 | €0.49 | x |
| 2023-12-31 | €0.22 | €0.49 | x |
| 2024-12-31 | €0.11 | €0.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bluelinea SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -89.92%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13.45%
- • Asset Turnover: 1.01x
- • Equity Multiplier: 6.64x
- Recent ROE (-89.92%) is below the historical average (-57.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 0.00% | -21.82% | 1.88x | 0.00x | €-57.91K |
| 2010 | -31.26% | -6.47% | 1.99x | 2.42x | €-52.56K |
| 2011 | -11.73% | -37.38% | 0.28x | 1.12x | €-327.00K |
| 2012 | -16.40% | -14.02% | 0.74x | 1.58x | €-585.03K |
| 2013 | -41.72% | -27.75% | 0.88x | 1.71x | €-1.01 Million |
| 2014 | -55.25% | -34.08% | 0.84x | 1.92x | €-1.90 Million |
| 2015 | -15.38% | -15.87% | 0.73x | 1.32x | €-1.89K |
| 2016 | -35.47% | -50.94% | 0.53x | 1.32x | €-4.25K |
| 2017 | -47.11% | -45.25% | 0.68x | 1.53x | €-3.63K |
| 2018 | -54.20% | -44.45% | 0.69x | 1.76x | €-3.24 Million |
| 2019 | -123.09% | -44.23% | 0.91x | 3.06x | €-3.02 Million |
| 2020 | -304.68% | -39.57% | 0.92x | 8.40x | €-2.79 Million |
| 2021 | 0.00% | -43.90% | 0.93x | 0.00x | €-3.12 Million |
| 2022 | -35.90% | -14.83% | 0.79x | 3.06x | €-1.97 Million |
| 2023 | -60.39% | -16.39% | 0.91x | 4.04x | €-1.89 Million |
| 2024 | -89.92% | -13.45% | 1.01x | 6.64x | €-1.41 Million |
Industry Comparison
This section compares Bluelinea SA's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $36,955,737
- Average return on equity (ROE) among peers: -32.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bluelinea SA (ALBLU) | €706.70K | 0.00% | 12.44x | $6.02 Million |
| Affluent Medical SAS (AFME) | $33.83 Million | -45.01% | 0.77x | $31.64 Million |
| Biosynex (ALBIO) | $124.31 Million | -29.72% | 0.94x | $7.06 Million |
| Carmat (ALCAR) | $-43.76 Million | 0.00% | 0.00x | $3.28 Million |
| Diagnostic Medical Systems SA (ALDMS) | $13.72 Million | -36.04% | 2.73x | $13.39 Million |
| Eurobio Scientific SA (ALERS) | $175.17 Million | 2.76% | 0.81x | $5.52 Million |
| Ikonisys SA (ALIKO) | $20.01 Million | -2.85% | 0.13x | $9.76 Million |
| Implanet SA (ALIMP) | $3.54 Million | -99.97% | 3.09x | $6.96 Million |
| Mediantechn (ALMDT) | $0.00 | 0.00% | 0.00x | $86.92 Million |
| Spineguard (ALSGD) | $5.77 Million | -78.70% | 0.48x | $5.70 Million |